Pain Management News and Research

RSS

Anesthesia Business Consultants launch F1RSTAccess mobile application

Anesthesia Business Consultants, LLC is singly focused on servicing their clients. ABC exploits the latest technological advancements to maximize information sharing with their clients. In line with this philosophy, ABC proudly announces the launch of their mobile application, F1RSTAccessTM.

11 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

9 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its second quarter ended June 30, 2010.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

Forensic Laboratories' analytical test capable of detecting Ethyl Sulfate in saliva

Forensic Laboratories, a Denver-based laboratory specializing in toxicology services for drug and alcohol abuse, has announced the expansion of its oral fluid testing capabilities. The company is the first lab in the nation to develop an analytical test capable of detecting Ethyl Sulfate (EtS) in saliva, a chemical produced by the body after alcohol exposure. Forensic Laboratories' new test method will also simultaneously detect Ethyl Glucuronide (EtG).

6 Aug 2010

RBC Life Sciences company-wide net sales rises to $7.8 million in second quarter

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.8 million for the second quarter ended June 30, 2010, compared to net sales of $6.8 million for the same period during 2009, an increase of 16%. Net sales for the six months ended June 30, 2010 also increased 16% to $14.8 million compared to net sales of $12.8 million during the same period in 2009.

4 Aug 2010

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

For patients with moderate pain after foot surgery, the cyclo-oxygenase 2 (COX-2) inhibitor drug etoricoxib provides better pain relief with fewer side effects than the opioid drug tramadol, concludes a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Aug 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

31 Jul 2010

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs. The Linear™ 3-4 and Linear™ 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians. The Company plans to launch the products immediately in the U.S.; they were launched in Europe and other international markets earlier.

30 Jul 2010

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Nearly half of all states are falling short on legislative solutions to prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN). However, despite budget crises in several states, some state lawmakers still made positive progress in the fight against a disease that will kill an estimated 569,000 people in the United States this year.

29 Jul 2010

Morphine blocks new blood vessel and tumor growth: Study

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

28 Jul 2010

Millennium Laboratories urges for increase in physician reimbursement for POC urine drug screening

Millennium Laboratories, Inc., a national, research-based medication monitoring company specifically focused on clinicians who treat chronic pain, strongly advocated for an increase in physician reimbursement for point-of-care urine drug screening at the Annual Clinical Laboratory Public Meeting of the Centers for Medicare and Medicaid Services on July 22, 2010.

27 Jul 2010

Researchers collect venom from Antarctic octopus

Australian and international researchers have collected venom from octopuses in Antarctica for the first time, significantly advancing our understanding of the properties of venom as a potential resource for drug-development.

27 Jul 2010

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

26 Jul 2010

New drug to treat chronic pain in SCD patients

A University of Minnesota Medical School research team led by Kalpna Gupta, Ph.D., has discovered that cannibinoids offer a novel approach to ease the chronic and acute pain caused by sickle cell disease.Using a mouse model of SCD, Gupta and University of Minnesota colleagues studied the pain mechanisms by observing animals that exhibited both musculoskeletal pain and temperature sensitivity, symptoms similarly experienced by humans with SCD. The team compared two classifications of drugs in their ability to manage pain sensed by the animals, the traditionally prescribed classification of drugs, opioids, with a new therapeutic approach, cannabinoids, a synthetic compound based on marijuana derivatives. Currently, the only approved treatment for management of severe pain in SCD is opioids.

23 Jul 2010

Winston Laboratories receives NOC for CIVANEX

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Jul 2010

Competitive Technologies anticipates $1M revenue from sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced it expects revenue from sales of its Calmare® Pain Therapy Treatment for the fourth quarter of fiscal 2010 to be about $1 million, nearly double that of the prior quarter. The Company expects significant additional growth in Calmare medical device sales in upcoming quarters resulting from the growing U.S. sales force of over 35 sales representatives.

19 Jul 2010

Investment report on Catalyst Pharmaceutical Partners

MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

12 Jul 2010